Doximity shares soar 21% after company beats on revenue, raises fiscal-year guidance

Doximity shares soar 21% after company beats on revenue, raises fiscal-year guidance


Doximity at the New York Stock Exchange for its initial public offering on June 24, 2021.

Source: NYSE

Shares of Doximity popped 21% on Thursday after the company reported third-quarter fiscal 2025 results that beat analysts’ expectations for revenue and offered rosy guidance.

Here’s how the company did:

  • Earnings per share: 37 cents, may not compare with the 34 cents expected by LSEG
  • Revenue: $168.6 million vs. $152.8 million expected by LSEG

Doximity is a digital platform for medical professionals that helps clinicians stay current on medical news, manage paperwork, find referrals and carry out telehealth appointments with patients. The company primarily generates revenue through its telehealth tools, hiring solutions and marketing offerings for clients such as pharmaceutical companies.

Doximity’s revenue increased 25% in its third quarter from $135.3 million during the same period last year, according to a release.

For its fiscal fourth quarter, Doximity said it expects to report revenue between $132.5 million and $133.5 million, compared with analysts’ estimates of $123.8 million.

The company also raised guidance for its full fiscal year, and said it expects to report revenue between $564.6 million and $565.6 million, up from the range the company shared last quarter, when it expected $535 million to $540 million. Analysts were expecting $540 million for the year.

“We’re proud to deliver another quarter of record engagement in Q3, with over 610,000 unique providers using our clinical workflow tools,” Doximity CEO Jeff Tangney said in a statement. “Our AI tools grew the fastest last quarter, up 60% over the prior quarter, while our newsfeed surpassed more than one million unique providers.”

The company reported net income of $75.2 million, or 37 cents per share, during its third quarter, up from $48.0 million, or 24 cents per share, a year prior. Doximity’s adjusted EBITDA was $102.0 million, up 39% year over year.

Doximity has been a bright spot within the battered digital health sector, which has faced a reckoning as companies have had to adjust to a more muted growth environment. The company’s stock price more than doubled in 2024.

Don’t miss these insights from CNBC PRO



Source

Fed minutes show officials were in tight split over December rate cut
World

Fed minutes show officials were in tight split over December rate cut

WASHINGTON – The Federal Reserve on Tuesday released minutes from its highly divisive meeting earlier this month, which concluded with a vote to lower interest rates again that appeared to be an even closer call than the final vote indicated. Officials expressed a variety of opinions during the Dec. 9-10 meeting, according to the summary […]

Read More
U.S. sanctions Iranian, Venezuelan groups tied to weapons trade
World

U.S. sanctions Iranian, Venezuelan groups tied to weapons trade

The U.S. on Tuesday announced sanctions on a group of 10 individuals and entities based in Iran and Venezuela that are allegedly linked to the weapons trade between the two countries. Those targeted include a Venezuelan company, Empresa Aeronautica Nacional, which is allegedly linked to millions of dollars of Iranian drone sales to Venezuela. The […]

Read More
These stocks had big turnarounds in 2025. Where analysts see them heading in 2026
World

These stocks had big turnarounds in 2025. Where analysts see them heading in 2026

After steep losses in 2024, stocks including Advanced Micro Devices and CVS Health managed to stage sharp rebounds this year — and analysts believe they may still some more room to run. An artificial intelligence-driven rally drove stocks broadly higher this year, with the S & P 500 on pace for a 17% year-to-date gain […]

Read More